2010/09/27

Blood test developed for non-alcoholic fatty liver disease diagnosis

The metabolomics-based blood test developed by OWL Genomics and
CIC bioGUNE will contribute to the early diagnosis of NASH, which
affects up to 24% of the US and European population.

"This is the first application of a novel experimental approach for blood
metabolomic profiling that can identify biomarkers for potentially any
liver disease", says professor José Mato.

OWL Genomics is beginning to commercialise this new test in Spain